Alembic Pharmaceuticals Limited (BOM:533573)
India · Delayed Price · Currency is INR 935.05
-15.15 (-1.59%)
At close: Aug 8, 2025
Exscientia Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 68,211 | 66,721 | 62,286 | 56,526 | 53,058 | 53,931 | Upgrade |
Other Revenue | -0.1 | -0.1 | - | - | - | - | Upgrade |
| 68,211 | 66,721 | 62,286 | 56,526 | 53,058 | 53,931 | Upgrade | |
Revenue Growth (YoY) | 8.20% | 7.12% | 10.19% | 6.54% | -1.62% | 17.10% | Upgrade |
Cost of Revenue | 18,941 | 18,808 | 17,961 | 17,748 | 14,982 | 13,402 | Upgrade |
Gross Profit | 49,270 | 47,913 | 44,325 | 38,778 | 38,076 | 40,529 | Upgrade |
Selling, General & Admin | 16,053 | 15,623 | 14,463 | 11,691 | 11,330 | 10,512 | Upgrade |
Other Operating Expenses | 22,634 | 22,153 | 20,500 | 19,892 | 17,951 | 15,213 | Upgrade |
Operating Expenses | 41,574 | 40,615 | 37,718 | 34,401 | 32,201 | 27,561 | Upgrade |
Operating Income | 7,696 | 7,298 | 6,607 | 4,378 | 5,875 | 12,968 | Upgrade |
Interest Expense | -891.1 | -787.7 | -561.9 | -501.7 | -177.3 | -160.2 | Upgrade |
Interest & Investment Income | 59.6 | 59.6 | 21 | 3.3 | 17.3 | 15.8 | Upgrade |
Earnings From Equity Investments | 1 | 8.7 | -9.8 | -309.2 | 52.8 | 317.4 | Upgrade |
Currency Exchange Gain (Loss) | 233.9 | 233.9 | 176.9 | -0.9 | 443.1 | 772.8 | Upgrade |
Other Non Operating Income (Expenses) | 122.3 | 78.3 | 3.9 | 2.4 | 0.5 | 1.7 | Upgrade |
EBT Excluding Unusual Items | 7,222 | 6,891 | 6,238 | 3,572 | 6,211 | 13,916 | Upgrade |
Gain (Loss) on Sale of Investments | 14.7 | 14.7 | 43.9 | 7.5 | 28.7 | 62.8 | Upgrade |
Gain (Loss) on Sale of Assets | 32.6 | 32.6 | 17 | -47 | 5.4 | 13.9 | Upgrade |
Other Unusual Items | 128.7 | 128.7 | - | - | - | - | Upgrade |
Pretax Income | 7,403 | 7,072 | 6,318 | 3,546 | 6,254 | 13,998 | Upgrade |
Income Tax Expense | 1,392 | 1,252 | 160 | 126.1 | 1,045 | 2,533 | Upgrade |
Earnings From Continuing Operations | 6,011 | 5,820 | 6,158 | 3,420 | 5,209 | 11,465 | Upgrade |
Minority Interest in Earnings | 19.9 | 14.1 | - | - | - | - | Upgrade |
Net Income | 6,031 | 5,834 | 6,158 | 3,420 | 5,209 | 11,465 | Upgrade |
Net Income to Common | 6,031 | 5,834 | 6,158 | 3,420 | 5,209 | 11,465 | Upgrade |
Net Income Growth | -4.26% | -5.26% | 80.07% | -34.35% | -54.56% | 38.33% | Upgrade |
Shares Outstanding (Basic) | 196 | 197 | 197 | 197 | 197 | 194 | Upgrade |
Shares Outstanding (Diluted) | 196 | 197 | 197 | 197 | 197 | 194 | Upgrade |
Shares Change (YoY) | -0.10% | - | - | - | 1.46% | 2.77% | Upgrade |
EPS (Basic) | 30.69 | 29.68 | 31.33 | 17.40 | 26.50 | 59.18 | Upgrade |
EPS (Diluted) | 30.69 | 29.68 | 31.33 | 17.40 | 26.50 | 59.18 | Upgrade |
EPS Growth | -4.16% | -5.26% | 80.07% | -34.35% | -55.22% | 34.60% | Upgrade |
Free Cash Flow | - | -4,757 | 4,757 | 2,805 | 1,267 | 8,039 | Upgrade |
Free Cash Flow Per Share | - | -24.20 | 24.20 | 14.27 | 6.45 | 41.49 | Upgrade |
Dividend Per Share | - | 11.000 | 11.000 | 8.000 | 10.000 | 14.000 | Upgrade |
Dividend Growth | - | - | 37.50% | -20.00% | -28.57% | 100.00% | Upgrade |
Gross Margin | 72.23% | 71.81% | 71.16% | 68.60% | 71.76% | 75.15% | Upgrade |
Operating Margin | 11.28% | 10.94% | 10.61% | 7.75% | 11.07% | 24.05% | Upgrade |
Profit Margin | 8.84% | 8.74% | 9.89% | 6.05% | 9.82% | 21.26% | Upgrade |
Free Cash Flow Margin | - | -7.13% | 7.64% | 4.96% | 2.39% | 14.90% | Upgrade |
EBITDA | 10,304 | 9,891 | 9,141 | 6,962 | 8,585 | 14,663 | Upgrade |
EBITDA Margin | 15.11% | 14.82% | 14.67% | 12.32% | 16.18% | 27.19% | Upgrade |
D&A For EBITDA | 2,608 | 2,593 | 2,533 | 2,584 | 2,710 | 1,695 | Upgrade |
EBIT | 7,696 | 7,298 | 6,607 | 4,378 | 5,875 | 12,968 | Upgrade |
EBIT Margin | 11.28% | 10.94% | 10.61% | 7.75% | 11.07% | 24.05% | Upgrade |
Effective Tax Rate | 18.80% | 17.70% | 2.53% | 3.56% | 16.70% | 18.10% | Upgrade |
Revenue as Reported | 68,680 | 67,146 | 62,569 | 56,554 | 53,563 | 54,804 | Upgrade |
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.